BR112016014617A2 - Variante do fator xa (fxa) e usos da referida variante - Google Patents

Variante do fator xa (fxa) e usos da referida variante

Info

Publication number
BR112016014617A2
BR112016014617A2 BR112016014617A BR112016014617A BR112016014617A2 BR 112016014617 A2 BR112016014617 A2 BR 112016014617A2 BR 112016014617 A BR112016014617 A BR 112016014617A BR 112016014617 A BR112016014617 A BR 112016014617A BR 112016014617 A2 BR112016014617 A2 BR 112016014617A2
Authority
BR
Brazil
Prior art keywords
variant
fxa
factor
compositions
methods
Prior art date
Application number
BR112016014617A
Other languages
English (en)
Inventor
Arkin Steven
Fruebis Joachim
E Carr Marcus
Hett Sunita
Jasuja Reema
D Pittman Debra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112016014617A2 publication Critical patent/BR112016014617A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA O TRATAMENTO DE HEMORRAGIA INTRACEREBRAL. A presente invenção refere-se a composições e métodos para o tratamento ou para a prevenção de hemorragia intracerebral (ICH) em um sujeito por administração de uma variante do FXa.
BR112016014617A 2014-01-24 2015-01-15 Variante do fator xa (fxa) e usos da referida variante BR112016014617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (1)

Publication Number Publication Date
BR112016014617A2 true BR112016014617A2 (pt) 2017-09-19

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014617A BR112016014617A2 (pt) 2014-01-24 2015-01-15 Variante do fator xa (fxa) e usos da referida variante

Country Status (18)

Country Link
US (2) US20160375109A1 (pt)
EP (1) EP3096779B1 (pt)
JP (1) JP6624787B2 (pt)
KR (3) KR20210008177A (pt)
CN (2) CN105934250A (pt)
AU (1) AU2015208819B2 (pt)
BR (1) BR112016014617A2 (pt)
CA (1) CA2937418A1 (pt)
DK (1) DK3096779T3 (pt)
ES (1) ES2772802T3 (pt)
HU (1) HUE047588T4 (pt)
IL (1) IL246637A0 (pt)
MX (1) MX2016009665A (pt)
PL (1) PL3096779T3 (pt)
PT (1) PT3096779T (pt)
RU (1) RU2016126423A (pt)
SI (1) SI3096779T1 (pt)
WO (1) WO2015110939A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014210830A1 (en) 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
WO2015044836A1 (en) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006144397A (ru) * 2004-06-21 2008-07-27 Ново Нордиск Хелс Кеа Аг (Ch) ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
CA2850603C (en) * 2011-09-30 2021-11-16 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
AU2014210830A1 (en) * 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition

Also Published As

Publication number Publication date
US20160375109A1 (en) 2016-12-29
HUE047588T2 (hu) 2020-04-28
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
DK3096779T3 (da) 2020-02-24
JP6624787B2 (ja) 2019-12-25
HUE047588T4 (hu) 2020-06-29
IL246637A0 (en) 2016-08-31
EP3096779A1 (en) 2016-11-30
SI3096779T1 (sl) 2020-03-31
EP3096779B1 (en) 2019-12-18
WO2015110939A1 (en) 2015-07-30
PT3096779T (pt) 2020-02-21
JP2015147764A (ja) 2015-08-20
CN105934250A (zh) 2016-09-07
KR20180014221A (ko) 2018-02-07
CA2937418A1 (en) 2015-07-30
RU2016126423A (ru) 2018-03-01
CN112156176A (zh) 2021-01-01
MX2016009665A (es) 2016-11-14
AU2015208819A1 (en) 2016-06-30
AU2015208819B2 (en) 2020-01-23
US20190231856A1 (en) 2019-08-01
ES2772802T3 (es) 2020-07-08
KR20160093731A (ko) 2016-08-08
RU2016126423A3 (pt) 2018-03-01

Similar Documents

Publication Publication Date Title
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
ECSP16075416A (es) Anticuerpos de il-21
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
FI3197556T3 (fi) Koostumus allergisten oireiden ennalta ehkäisemiseksi ja/tai hoitamiseksi
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
BR112016014617A2 (pt) Variante do fator xa (fxa) e usos da referida variante
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
BR112016019395A2 (pt) composição
MX357132B (es) Uso de la inulina para el tratamiento de manifestaciones clínicas asociadas con la cirrosis hepática.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2705 DE 08-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.